Clinical Trials Browser

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT04590235 2026-01-30

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Phase 1 Active not recruiting

32 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05363267 2026-01-13

NF-1, Nutraceutical Intervention

Phase 1 Active not recruiting

23 enrolled

CNS

Neurofibromatosis 1

NCT04924608 2026-01-12

KOMET

Phase 3 Active not recruiting

145 enrolled 17 charts 1 FDA

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05309668 2025-12-18

SPRINKLE

Phase 1/2 Active not recruiting

36 enrolled 37 charts

CNS

Neurofibromatosis 1

NCT03962543 2025-08-07

ReNeu

Phase 2 Active not recruiting

114 enrolled 25 charts 1 FDA

CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT02964884 2025-06-24

Interventions for Reading Disabilities in NF1

Phase 2 Active not recruiting

120 enrolled

CNS

Dyslexia, Learning Disabilities, Neurofibromatosis 1

NCT05913037 2025-03-06

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Phase 3 Active not recruiting

167 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04954001 2024-11-12

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Phase 1/2 Active not recruiting

160 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04481048 2024-10-09

DoDNAC

Phase 2 Active not recruiting

58 enrolled

CNS

Neurofibromatosis 1

NCT03741101 2024-04-11

plexifpc

Phase 2 Active not recruiting

15 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03363217 2023-11-27

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Phase 2 Active not recruiting

114 enrolled

CNS

Brain Neoplasms, Glioma, Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03820778 2021-03-02

Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1

Phase NA Active not recruiting

10 enrolled

CNS

Neurofibromatosis, type 4, of Riccardi, Neurofibroma, Neurofibromatosis 1, Neurofibroma, Plexiform

Clinical Trials

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Pediatric Long-Term Follow-up and Rollover Study

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

NF-1, Nutraceutical Intervention

KOMET

SPRINKLE

ReNeu

Interventions for Reading Disabilities in NF1

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

DoDNAC

plexifpc

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1